Trial · NCT00832377
COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
NCT00832377, Phase 2, Completed, Merck Sharp & Dohme LLC; results first posted 2011-03-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED). Trials, record NCT00832377. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00832377
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
- NCT number
- NCT00832377
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 37 participants, actual
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Glaucoma
- Interventions
- timolol/dorzolamide combination
- First posted
- 2009-01-30
- Last updated
- 2017-09-29
- Results first posted
- 2011-03-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change in the Peak Intraocular Pressure (IOP) Measured Two Hours After Study Drug Administration at Week 12 Compared to Baseline IOP. | Baseline and 12 weeks | The therapeutic goal of normal tension glaucoma treatment includes lowering IOP to prevent progression of damage in optic nerves or vision. In this trial, IOP was measured with the same tonometer throughout the study. A decreased IOP from baseline is considered an improvement. IOP was measured in both eyes and the eye with the higher IOP was used for the participant. |
| Secondary | Mean Change in Trough IOP Measured Right Before Study Drug Administration at Week 12 Compared to Baseline IOP. | Baseline and 12 weeks | The therapeutic goal of normal tension glaucoma treatment includes lowering IOP to prevent progression of damage in optic nerves or vision. In this trial, IOP was measured with the same tonometer throughout the study. A decreased IOP from baseline is considered an improvement. IOP was measured in both eyes and the eye with the higher IOP was used for the participant. |
| Secondary | Mean Change in IOP 8 Hours After the Study Drug Administration at Week 12 Compared to Baseline IOP | Baseline and 12 weeks | The therapeutic goal of normal tension glaucoma treatment includes lowering IOP to prevent progression of damage in optic nerves or vision. In this trial, IOP was measured with the same tonometer throughout the study. A decreased IOP from baseline is considered an improvement. IOP was measured in both eyes and the eye with the higher IOP was used for the participant. |
| Other | Baseline IOP | Baseline | Baseline IOP was measured at \~9 AM of first day of treatment period. IOP was measured in both eyes and the eye with the higher IOP was used for the participant. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change in the Peak Intraocular Pressure (IOP) Measured Two Hours After Study Drug Administration at Week 12 Compared to Baseline IOP. | Baseline and 12 weeks | mmHg | MEAN | |
| SECONDARY | Mean Change in Trough IOP Measured Right Before Study Drug Administration at Week 12 Compared to Baseline IOP. | Baseline and 12 weeks | mmHg | MEAN | |
| SECONDARY | Mean Change in IOP 8 Hours After the Study Drug Administration at Week 12 Compared to Baseline IOP | Baseline and 12 weeks | mmHg | MEAN | |
| OTHER_PRE_SPECIFIED | Baseline IOP | Baseline | mmHg | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change in the Peak Intraocular Pressure (IOP) Measured Two Hours After Study Drug Administration at Week 12 Compared to Baseline IOP. | Timolol/Dorzolamide | -3.73 | Standard Deviation 2.28 | mmHg | |
| Mean Change in Trough IOP Measured Right Before Study Drug Administration at Week 12 Compared to Baseline IOP. | Timolol/Dorzolamide | -3.22 | Standard Deviation 2.14 | mmHg | |
| Mean Change in IOP 8 Hours After the Study Drug Administration at Week 12 Compared to Baseline IOP | Timolol/Dorzolamide | -3.78 | Standard Deviation 2.40 | mmHg | |
| Baseline IOP | Timolol/Dorzolamide | 15.60 | Standard Deviation 2.46 | mmHg |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Timolol/Dorzolamide | 37 | |
| Overall Study | COMPLETED | Timolol/Dorzolamide | 36 | |
| Overall Study | NOT COMPLETED | Timolol/Dorzolamide | 1 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Eye irritation | Eye disorders | Timolol/Dorzolamide | 22 | 37 | 32 |
| other | Ocular hyperaemia | Eye disorders | Timolol/Dorzolamide | 6 | 37 | 6 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Timolol/Dorzolamide | 2 | 37 | 2 |
| other | Headache | Nervous system disorders | Timolol/Dorzolamide | 2 | 37 | 2 |
| other | Rash | Skin and subcutaneous tissue disorders | Timolol/Dorzolamide | 2 | 37 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Timolol/Dorzolamide | ||
| Total, other adverse events | Timolol/Dorzolamide | 24 | 37 |
| Total, serious adverse events | Timolol/Dorzolamide | 0 | 37 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23377586 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00832377
GET https://conductscience.org/api/trials/v1/NCT00832377/registered